Highest development stage: Phase 1

Development dropped

Gram-negative activity

Mechanism of Action/Target pathogen: Activity against MRSA and CAP

Reason dropped: Pfizer and Daiichi announced discontinuation of this antibiotic in 2004 after analysis of Phase I trial data